Biotech · Private company
GTx
Track this companyFree. Adds GTx to your Dealase workspace and tells you when its record changes.
Clinical trials140 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- GTx-024Phase 3 · Muscle WastingClinicalTrials.gov · fetched Nov 12, 2026
- Toremifene 20 mgPhase 3 · Preneoplastic ConditionsClinicalTrials.gov · fetched Nov 12, 2026
- GTx-024Phase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- GTx-024Phase 2 · ER+ and AR+ Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- GTx-024Phase 2 · Stress Urinary IncontinenceClinicalTrials.gov · fetched Nov 12, 2026
- GTx-024 9 or 18 mgPhase 2 · ER+ and AR+ Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- GTx-024 9mgPhase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- GTx-758Phase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- GTx-758 1000mgPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- GTx-758 125 mgPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- GTx-758 2000mgPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- GTx-758 250 mgPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Lupron DepotPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials14
- Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary IncontinencePHASE2 · WITHDRAWN · started Jun 28, 2018ClinicalTrials.gov NCT03566290 · fetched Nov 12, 2026
- Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary IncontinencePHASE2 · WITHDRAWN · started May 28, 2018ClinicalTrials.gov NCT03508648 · fetched Nov 12, 2026
- Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary IncontinencePHASE2 · COMPLETED · started Aug 21, 2017ClinicalTrials.gov NCT03241342 · fetched Nov 12, 2026
- Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body MassPHASE2 · WITHDRAWN · started Apr 1, 2016ClinicalTrials.gov NCT02746328 · fetched Nov 12, 2026
- GTx-024 as a Treatment for Stress Urinary Incontinence in WomenPHASE2 · COMPLETED · started Jan 1, 2016ClinicalTrials.gov NCT02658448 · fetched Nov 12, 2026
- Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast CancerPHASE2 · COMPLETED · started Aug 1, 2015ClinicalTrials.gov NCT02463032 · fetched Nov 12, 2026
- Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)PHASE2 · TERMINATED · started Jun 1, 2015ClinicalTrials.gov NCT02368691 · fetched Nov 12, 2026
- Phase II Study of GTx024 in Women With Metastatic Breast CancerPHASE2 · TERMINATED · started Apr 1, 2013ClinicalTrials.gov NCT01616758 · fetched Nov 12, 2026
- Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate CancerPHASE2 · COMPLETED · started Aug 14, 2012ClinicalTrials.gov NCT01615120 · fetched Nov 12, 2026
- GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate CancerPHASE2 · TERMINATED · started Sep 1, 2011ClinicalTrials.gov NCT01420861 · fetched Nov 12, 2026
- Phase II, Dose Finding Study of GTx-758PHASE2 · TERMINATED · started Aug 1, 2011ClinicalTrials.gov NCT01393119 · fetched Nov 12, 2026
- Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line PlatinumPHASE3 · COMPLETED · started Jul 1, 2011ClinicalTrials.gov NCT01355497 · fetched Nov 12, 2026
- Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate CancerPHASE2 · TERMINATED · started Jun 1, 2011ClinicalTrials.gov NCT01326312 · fetched Nov 12, 2026
- Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)PHASE3 · COMPLETED · started Jan 1, 2005ClinicalTrials.gov NCT00106691 · fetched Nov 12, 2026